Year-end report 1 January–31 December 2025

Asker Healthcare delivered robust FY2025 results with net sales of SEK 16,787m (+12%) and adjusted EBITA of SEK 1,594m (+17%) yielding a 9.5% adjusted EBITA margin; Q4 net sales were SEK 4,676m (+9%) and adjusted EBITA SEK 470m (+16%) with a 10.0% adjusted EBITA margin. Full-year EBIT was SEK 1,009m, profit SEK 510m, EPS SEK 1.25, and cash flow from operations SEK 1,328m. The board proposed a SEK 0.39 per-share dividend (previously 0) and the company signed agreements for four acquisitions in the UK, Switzerland, France and the Netherlands, signaling continued M&A-driven growth and attainment of its 10% margin target.

Analysis

Market structure: Asker’s 2025 results and four announced tuck‑ins accelerate consolidation in European med‑tech distribution — winners are local specialist distributors (sell to strategic consolidators) and Asker itself via scale-driven margin expansion (adjusted EBITA margin reached 10%). Losers are fragmented midsize competitors and price‑sensitive suppliers with limited negotiating leverage; expect modest pricing pressure on commoditised SKUs but better mix/pricing on speciality devices. Cross‑asset: positive for Asker equity and EUR corporate credit spreads; implied equity vol should compress if M&A cadence continues; SEK may see modest support from the proposed dividend (SEK 0.39).

Key Decisions for Investors

• Establish a 2–3% long position in Asker Healthcare Group AB (Asker) within 5 trading days, target 25% upside in 12 months, stop‑loss at -12%; add up to +1% on any >8% pullback if Q1 trading commentary confirms continued organic growth.
• Implement a 1:1 pair trade for 6–12 months: long Asker (notional) vs short Fresenius (FRE.DE) equal notional exposure, profit if Asker outperforms on roll‑up margin expansion; close if relative move exceeds ±15% adverse or either company issues unexpected leverage guidance.
• Buy a 12‑month call spread on Asker (buy ATM, sell ~30% OTM) sized to 1–2% portfolio risk, only if Asker’s 12‑month implied vol <35%; target 3x payoff, max loss = premium paid.
• Reallocate +3% portfolio weight into European healthcare distribution/specialty medtech names (funded from -3% cyclical industrials); revisit after Q1 2026 results and any EU antitrust developments within 60–90 days.